Lucio Petruzziello

Lucio Petruzziello

Auto-generated profile, based on publicly available information

Lucio Petruzziello

Agostino Gemelli University Policlinic, Rome, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Journal of Ultrasound in Medicine
Verified
Journal Article
Open access
PDF file
ATAntonia Carla Testa
Antonia Carla Testa
ALAngelo Licameli
Angelo Licameli
ALAlessia Di Legge
Alessia Di Legge
FMFloriana Mascilini
Floriana Mascilini
LPLucio Petruzziello
Lucio Petruzziello
Gabriella FerrandinaGabriella Ferrandina
Gabriella Ferrandina

1 May 2023 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
SPSilvia Pecere
Silvia Pecere
CCCristina Ciuffini
Cristina Ciuffini
MCMichele Francesco Chiappetta
Michele Francesco Chiappetta
LPLucio Petruzziello
Lucio Petruzziello
LPLuigi Giovanni Papparella
Luigi Giovanni Papparella
FBFederico Barbaro
Federico Barbaro
Colorectal cancer (CRC) is a major health issue, being responsible for nearly 10% of all cancer-related deaths. Since CRC is often an asymptomatic or paucisymptomatic disease until it reaches advanced stages, screening is crucial for the diagnosis of preneoplastic lesions or early CRC. The aim of this review is to summarize the literature evidence on currently available CRC screening tools, with their pros and cons, focusing on the level of accuracy reached by each test over time. We also provide an overview of novel technologies and scientific advances that are currently being investigated and that in the future may represent real game-changers in the field of CRC screening. We suggest that best screening modalities are annual or biennial FIT and colonoscopy every 10 years. We believe that the introduction of artificial intelligence (AI)-tools in the CRC screening field could lead to a significant improvement of the screening efficacy in reducing CRC incidence and mortality in the future. More resources should be put into implementing CRC programmes and support research project to further increase accuracy of CRC screening tests and strategies.

1 January 2014 in Digestive and Liver Disease
Verified
Journal Article
Closed access
GAGianluca Andrisani
Gianluca Andrisani
LPLucio Petruzziello
Lucio Petruzziello
RRRiccardo Ricci
Riccardo Ricci
CSCristiano Spada
Cristiano Spada
Guido CostamagnaGuido Costamagna
Guido Costamagna

1 September 2004 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Alfredo CesarioAlfredo Cesario
Alfredo Cesario
DGDomenico Galetta
Domenico Galetta
SMStefano Margaritora
Stefano Margaritora
ATAndrea Tringali
Andrea Tringali
LPLucio Petruzziello
Lucio Petruzziello
PGPierluigi Granone
Pierluigi Granone

8 March 2022 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
GCGiuditta Chiloiro
Giuditta Chiloiro
EMElisa Meldolesi
Elisa Meldolesi
BCBarbara Corvari
Barbara Corvari
ARAngela Romano
Angela Romano
BBBrunella Barbaro
Brunella Barbaro
MGMaria Antonietta Gambacorta
Maria Antonietta Gambacorta
Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the standard of care for locally advanced rectal cancer (LARC). Several studies have shown a correlation between a longer interval between the end of nCRT and surgery (surgical interval - SI) and an increased pathological complete response (pCR) rate, with a maximum obtained between 10 and 13 weeks. The primary endpoint of this multicenter, 2-arm randomised trial is to investigate SI lengthening, evaluating the difference in terms of complete response (CR) and Tumor Regression Grade (TRG)1 rate in the two arms. Secondly, the impact of SI lengthening on survival outcomes and quality of life (QoL) will be investigated. Intermediate-risk LARC patients undergoing nCRT will be prospectively included in the study. nCRT will be administered with a total dose of 55 Gy in 25 fractions on Gross Tumor Volume (GTV) plus the corresponding mesorectum of 45 Gy in 25 fractions on the whole pelvis. Chemotherapy with oral capecitabine will be administered continuously. The patients achieving a clinical major or complete response assessed at clinical-instrumental re-evaluation at 7–8 weeks after treatment completion, will be randomized into two groups, to undergo surgery or local excision at 9–11 weeks (control arm) or at 13–16 weeks (experimental arm). Pathological response will be assessed on the surgical specimen using the AJCC TNM v.7 and the TRG according to Mandard. Patients will be followed up to evaluate toxicity and QoL. The promoter center of the trial will conduct the randomization process through an automated procedure to prevent any possible bias. For sample size calculation, using CR difference of 20% as endpoint, 74 patients per arm will be enrolled. The results of this study may prospectively provide a new time frame for the clinical re-evaluation for complete/major responders patients in order to increase the CR rate to nCRT. Trial registration: ClinicalTrials.gov Identifier: NCT03581344.

14 April 2023 in Endoscopy
Verified
Journal Article
Closed access
MCM. F. Chiappetta
M. F. Chiappetta
LPL. G. Papparella
L. G. Papparella
FBFederico Barbaro
Federico Barbaro
CCC. Ciuffini
C. Ciuffini
LPL. Petruzziello
L. Petruzziello
CSCristiano Spada
Cristiano Spada
Aims Endoscopic mucosal resection (EMR) of superficial non-ampullary duodenal epithelial tumor (SNADETs) is often challenging, and to date, there are few studies assessing the clinical outcomes of EMR in the duodenum. The aim of this study was to evaluate the efficacy and safety of EMR for the treatment of SNADETs >10 mm. Methods This is a retrospective observational single-center study reporting data from a cohort of consecutive patients undergoing EMR of SNADETs between January 2017 and December 2021. Results A total of 81 patients with 83 lesions underwent EMR (70 conventional EMR, 13 underwater EMR). Complete EMR was performed in all cases. The mean size was 24 ± 13 mm. The mean procedure time was 45 ± 30 min and the en-bloc resection rate was 47%. Delayed bleeding occurred in 5 (6%) of EMRs. Only one perforation was observed, which was managed surgically. Recurrence rate was 20% with a median follow-up of 13 months and all the recurrences were treated endoscopically. Lesion size (p=0.02), previous endoscopic resection (p=0.05), previous biopsy (p= <0.001) and piecemeal resection (p= 0.004) were associated with local/residual recurrence ([Table 1]). Conclusions Large duodenal adenomas can be effectively managed with EMR in a referral center. However, EMR has a significant recurrence rate, and the risk of adverse events is not negligible. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany